CARPL.ai

CARPL.ai's pitch is narrow and specific: stop integrating radiology AI one vendor at a time. The mechanism is a single technical integration to your PACS and RIS, behind which sits a marketplace the vendor now describes as 300+ AI applications from 100+ vendors. That is the whole argument, and it is a good one for any organization whose AI portfolio is growing faster than its IT capacity. What makes CARPL more than a catalog is the validation layer. You run a candidate algorithm live on your own imaging data, then pull a single-click report with an interactive statistical summary, an AUC-ROC curve, a confusion matrix and side-by-side visualization of false-positive and false-negative cases. That changes the procurement conversation from "what does the vendor's white paper say" to "what does this model do on our scanner, our population, our protocol." Post-deployment monitoring then keeps tracking those models after go-live, which is where most AI programs quietly fail. If the reports are honest, they are the most valuable thing on the platform — and the caveat is symmetric: a narrow case mix yields narrow evidence, so the output is only as good as what you feed it. Day-to-day operationally, the pieces are sensible rather than flashy. The universal AI viewer handles the awkward output formats radiology AI actually produces — probability scores, ROI coordinates, secondary captures, structured reports, DICOM PDF, GSPS DICOM, DICOM segmentation — instead of forcing each vendor's viewer into your reading room. Automatic series identification routes each study to the right algorithm, and report auto-population, intelligent triaging and urgency flagging are the workflow features that decide whether radiologists actually use the thing. Role-based access control plus a single sign-on portal keeps user management in one place, and the platform is infrastructure-agnostic: on-premise or cloud, any cloud vendor. Enterprise-grade security and simplified change management are claimed but not detailed in public material, so evaluate those in a pilot rather than from the brochure. For AI developers the platform is a distribution channel as much as a runtime: deployment across the United States, Brazil, Singapore, Australia and India, real-time user insights, and support for research and validation studies including CE and FDA regulatory pathways. That is unusual — most orchestration layers sell only to the hospital side — and it is why the marketplace reached the 300+ application mark. Where CARPL does not fit: a single clinic buying one chest X-ray or mammography algorithm, a practice without the IT capacity to handle one PACS/RIS integration, or a site that will never run more than one or two models. The platform is a layer, so you pay orchestration on top of whatever the individual apps cost, and some marketplace applications carry their own licensing fees. On-premise deployment demands real infrastructure and ongoing attention. The buyer who gets the